Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 1171-1178

  Min, Suk Kim ^a   Wan, Hyeong Cho ^a   Won, Seok Song ^a   Lee, Soo Yong ^a   Jeon, Dae Geun ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Ezrin; Metastasis; MFH; Prognosis

Indexed keywords

EZRIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; CYTOSKELETAL PROTEINS; FEMALE; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 34247126202     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Oda Y, Tamiya S, Oshiro Y, Hachitanda Y, Kinukawa N, Iwamoto Y and Tsuneyoshi M: Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int 52: 595-606, 2002.
2. Ahlen J, Weng WW, Brosjo O, Von Rosen A, Larsson O and Larsson C: Evaluation of immunohistochemical parameters as prognostic markers in malignant fibrous histiocytoma. Oncol Rep 10: 1641-1645, 2003.
3. Asano N, Yamakazi T, Seto M, Matsumine A, Yoshikawa H and Uchida A: The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma. J Bone Joint Surg Br 86: 607-612, 2004.
4. Engellau J, Persson A, Bendahl PO, Akerman M, Domanski HA, Bjerkehagen B, Lilleng P, Weide J, Rydholm A, Alvegard TA and Nilbert M: Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Virchows Arch 445: 224-230, 2004.
5. Weng WH, Wejde J, Ahlen J, Pang ST, Lui WO and Larsson C: Characterization of large chromosome markers in a malignant fibrous histiocytoma by spectral karyotyping, comparative genomic hybridization (CGH), and array CGH. Cancer Genet Cytogenet 150: 27-32, 2004.
6. Fletcher CD, Gustafson P, Rydholm A, Willen H and Akerman M: Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 19: 3045-3050, 2001.
7. Massi D, Beltrami G, Capanna R and Franchi A: Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance. Eur J Surg Oncol 30: 1131-1136, 2004.
8. Yonemoto T, Tatezaki S, Ishii T, Iwata S, Takeuchi Y and Araki A: Histological vascular invasion by tumors is a risk factor for distant metastasis in malignant fibrous histiocytoma. Anticancer Res 25: 1337-1342, 2005.
9. Fletcher CDM, van den Berg E and Molenaar WM: Pleomorphic malignant fibrous histiocytoma/undifferentiated high grade pleomorphic sarcoma. In: Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, and Mertens F (eds.). Lyon, IARC, pp. 120-122, 2002.
10. Tos AP: Classification of pleomorphic sarcomas: where are we now? Histopathology 48: 51-62, 2006.
11. Deyrup AT, Haydon RC, Huo D, Ishikawa A, Peabody TD, He TC and Montag AG: Myoid differentiation and prognosis in adult pleomorphic sarcomas of the extremity: an analysis of 92 cases. Cancer 98: 805-813, 2003.
12. Curto M and McClatchey AI: Ezrin - a metastatic determinant? Cancer Cell 5: 113-114, 2004.
13. Martin TA, Harrison G, Mansel RE and Jiang WG: The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46: 165-186, 2003.
14. McClatchey AI: Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer 3: 877-883, 2003.
15. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P and Helman L: Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61: 3750-3759, 2001.
16. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10: 182-186, 2004.
17. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS and Merlino G: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10: 175-181, 2004.
18. Akisawa N, Nishimori I, Iwamura T, Onishi S and Hollingsworth MA: High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 258: 395-400, 1999.
19. Madan R, Brandwein-Gensler M, Schlecht NF, Elias K, Gorbovitsky E, Belbin TJ, Mahmood R, Breining D, Qian H, Childs G, Locker J, Smith R, Haigentz M Jr, Gunn-Moore F and Prystowsky MB: Differential tissue and subcellular expressionof ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic signficance for head and neck squamous cell carcinoma. Head Neck 28: 1018-1027, 2006.
20. Kobel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, Wolters M, Dittmer J, Strauss HG, Thomssen C and Hauptmann S: Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 25: 121-130, 2006.
21. Zeng H, Xu L, Xiao D, Zhang H, Wu X, Zheng R, Li Q, Niu Y, Shen Z and Li E: Altered expression of ezrin in esophageal squamous cell carcinoma. J Histochem Cytochem 54: 889-896, 2006.
22. Kobel M, Langhammer T, Huttelmaier S, Schmitt WD, Kriese K, Dittmer J, Strauss HG, Thomssen C and Hauptmann S: Ezrin expression is related to poor prognosis in FIGO Stage I endometrioid carcinomas. Mod Pathol 19: 581-587, 2006.
23. Weng WH, Ahlen J, Astrom K, Lui WO and Larsson C: Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 11: 6198-6204, 2005.
24. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X and Costa J: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15: 350-362, 1997.
25. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller CM and Morrow M: Soft tissue sarcoma. In: AJCC Cancer Staging Manual. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller CM and Morrow M (eds.). New York, Springer, pp. 193-197, 2002.
26. Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 153: 106-120, 1980.
27. Geiger KD, Stoldt P, Schlote W and Derouiche A: Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 157: 1785-1793, 2000.
28. Ilmonen S, Vaheri A, Asko-Seljavaara S and Carpen O: Ezrin in primary cutaneous melanoma. Mod Pathol 18: 503-510, 2005.
29. Moilanen J, Lassus H, Leminen A, Vaheri A, Butzow R and Carpen O: Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol 90: 273-281, 2003.
30. Pang ST, Fang X, Valdman A, Norstedt G, Pousette A, Egevad L and Ekman P: Expression of ezrin in prostatic intraepithelial neoplasia. Urology 63: 609-612, 2004.
31. Camp RL, Chung GG and Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323-1327, 2002.
32. Tzankov A, Zimpfer A, Went P, Maurer R, Pileri SA, Geley S and Dirnhofer S: Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. Mod Pathol 18: 90-96, 2005.
33. Hsu HC, Huang EY and Wang CJ: Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol 43: 530-535, 2004.
34. Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, Bonichon F, Collin F, Mandard AM and Contesso G: Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer 77: 1823-1830, 1996.
35. Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA and Fletcher CD: Myxofibrosarcoma. Clinicopathological analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 20: 391-405, 1996.
36. Peiper M, Zurakowski D, Knoefel WT and Izbicki JR: Malignant fibrous histiocytoma of the extremities and trunk: an institutional review. Surgery 135: 59-66, 2004.
37. Salo JC, Lewis JJ, Woodruff JM, Leung DH and Brennan MF: Malignant fibrous histiocytoma of the extremity. Cancer 85: 1765-1772, 1999.
38. Deyrup AT and Weiss SW: Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world. Histopathology 48: 42-50, 2006.
39. Hunter KW: Ezrin, a key component in tumor metastasis. Trends Mol Med 10: 201-204, 2004.
40. Davis AM, Kandel RA, Wunder JS, Unger R, Meer J, O'Sullivan B, Catton CN and Bell RS: The impact of residual disease on local recurrence in patients treated by initial unplanned resection for soft tissue sarcoma of the extremity. J Surg Oncol 66: 81-87, 1997.
41. Lewis JJ, Leung D, Heslin M, Woodruff JM and Brennan MF: Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 15: 646-652, 1997.
42. Eilber FC, Eilber FR, Eckardt J, Rosen G, Riedel E, Maki RG, Brennan MF and Singer S: The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 240: 686-695; discussion 695-697, 2004.
43. Zagars GK, Goswitz MS and Pollack A: Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy. Int J Radiat Oncol Biol Phys 36: 311-319, 1996.
44. Wan X, Mendoza A, Khanna C and Helman LJ: Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65: 2406-2411, 2005.
45. Engellau J, Anderson H, Rydholm A, Bauer HC, Hall KS, Gustafson P, Akerman M, Meis-Kindblom J, Alvegard TA, Nilbert M and Scandinavian Sarcoma Group: Time dependence of prognostic factors for patients with soft tissue sarcoma: a Scandinavian Sarcoma Group Study of 338 malignant fibrous histiocytomas. Cancer 100: 2233-2239, 2004.